Oncology

Combining cancer drugs may help prevent drug resistance.

A look at last week's top stories in the world of pharmacy.

Multiple mutations may work together to develop drug-resistant non-small cell lung cancer.

Direct-acting antivirals drugs show similar cure rates in co-infected patients as high as mono-infected patients.

A cancer diagnosis in young patients can cause post-traumatic stress disorder that can persist long afterwards.

Medicare sequester cuts could restrict access to care for seniors with cancer.

Doubling Medicare sequester cuts could reduce access to lower-cost cancer treatment.

Only 15% of patients with a 20% to 24% risk of breast cancer received a recommended MRI screening.

A look at last week's top stories in the world of pharmacy.

Sunitinib malate (Sutent) is an adjuvant therapy for adults at risk of recurrent renal cell carcinoma following nephrectomy.

Fulvestrant (Faslodex) plus abemaciclib may improve progression-free survival among patients with advanced or metastatic breast cancer.

Exposure to ammonia found to amplify breast cancer cell proliferation.

Nine other countries are on track to eliminate the hepatitis C virus by 2030.

Top news of the week from Specialty Pharmacy Times.

Study finds association between warfarin use and cancer incidence to determine whether warfarin has anticancer potential.

Heplisav-B is the only 2-dose hepatitis B vaccine recombinant approved in the United States.

Brentuximab vedotin (Adcetris) improves survival among patients with anaplastic large cell lymphoma or CD30-expressing mycosis fungoides.

Brentuximab vedotin (Adcetris) improves survival among patients with anaplastic large cell lymphoma or CD30-expressing mycosis fungoides.

Ribociclib (Kisqali) combination therapy may improve survival among premenopausal breast cancer patients.

A comprehensive knowledge of the risk of breast cancer can lead to better screening.

Patients without cirrhosis who achieved a sustained virological response had the lowest risk of hepatocellular carcinoma linked to hepatitis C virus.

Patients with hepatitis C who achieved sustained virologic response with a direct-acting antiviral maintained health improvements that enhanced their long-term quality of life.

Alectinib (Alecensa) found to significantly improve progression-free survival among patients with lung cancer.

Alectinib (Alecensa) found to reduce the risk of disease progression in patients with metastatic non-small cell lung cancer.

An aspirin a day may reduce their risk of hepatocellular carcinoma in patients with hepatitis B virus.

Trastuzumab monotherapy was not linked to surgical complications among patients with breast cancer undergoing reconstruction after a mastectomy.